Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population - PubMed (original) (raw)

Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population

Wah-Kheong Chan et al. United European Gastroenterol J. 2017 Feb.

Abstract

Background: The FibroScan® XL probe reduces failure of liver stiffness measurement (LSM) and unreliable results in obese patients.

Objective: The objective of this article is to evaluate the accuracy of controlled attenuation parameter (CAP) obtained using the XL probe for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease (NAFLD).

Methods: Adult NAFLD patients with a liver biopsy within six months were included and were examined with the FibroScan® M and XL probes. Histopathological findings were reported according to the Non-Alcoholic Steatohepatitis Clinical Research Network Scoring System. Participants who did not have fatty liver on ultrasonography were recruited as controls.

Results: A total of 57 NAFLD patients and 22 controls were included. The mean age of the NAFLD patients and controls was 50.1 ± 10.4 years and 20.2 ± 1.3 years, respectively (p = 0.000). The mean body mass index was 30.2 ± 5.0 kg per m2 and 20.5 ± 2.4 kg per m2, respectively (p = 0.000). The distribution of steatosis grades were: S0, 29%; S1, 17%; S2, 35%; S3, 19%. The AUROC for estimation of steatosis grade ≥ S1, S2 and S3 was 0.94, 0.80 and 0.69, respectively, using the M probe, and 0.97, 0.81 and 0.67, respectively, using the XL probe.

Conclusion: CAP obtained using the XL probe had similar accuracy as the M probe for the estimation of hepatic steatosis in NAFLD patients.

Keywords: CAP; FibroScan; LSM; NAFLD; Non-alcoholic fatty liver disease; XL probe; controlled attenuation parameter; fibrosis; liver stiffness measurement; steatosis.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Controlled attenuation parameter according to steatosis grade using the M probe and the XL probe. The Kruskal-Wallis test was used for comparison across groups. The number of individuals in each steatosis grade is indicated at the top of the corresponding boxplot. There was one non-alcoholic fatty liver disease (NAFLD) patient and 22 healthy controls in the steatosis grade 0 group.

Figure 2.

Figure 2.

Liver stiffness measurement according to fibrosis stage using the M probe and the XL probe. The Kruskal-Wallis test was used for comparison across groups. The number of individuals in each fibrosis stage is indicated at the top of the corresponding boxplot. There were 23 non-alcoholic fatty liver disease (NAFLD) patients and 22 healthy controls in the fibrosis stage 0 group.

References

    1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of non-alcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. Epub ahead of print 28 December 2015. DOI: 10.1002/hep.28431. - PubMed
    1. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409–415. - PubMed
    1. Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int 2013; 7: 548–554. - PubMed
    1. Chan WK, Tan AT, Vethakkan SR, et al. Non-alcoholic fatty liver disease in diabetics—prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol 2013; 28: 1375–1383. - PubMed
    1. Chan WK, Bahar N, Razlan H, et al. Non-alcoholic fatty liver disease in a young multiracial Asian population—a worrying ethnic predilection in Malay and Indian males. Hepatol Int 2014; 8: 121–127. - PubMed

LinkOut - more resources